Date:5/15/2012

ations, assumptions, estimates and projections.  While the Company believes these expectations, assumptions, estimates and projections are reasonable, such forward-looking statements are only predictions and involve known and unknown risks and uncertainties, many of which are beyond the Company's control. These and other important factors, including those discussed under "Risk Factors" in the Company's Form 10-K for the year ended June 25, 2011, as well as the Company's subsequent filings with the Securities and Exchange Commission, may cause actual results, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. The forward-looking statements in this press release are made only as of the date hereof, and unless otherwise required by applicable securities laws, the Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

'/>"/>

SOURCE Perrigo Company Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2
Related medicine technology :

1. Perrigo Reports Record Third Quarter Revenue And Earnings And Raises Full Year EPS Guidance
2. Perrigo Company Will Release Third Quarter Fiscal 2012 Results On May 8, 2012
3. Perrigo Company to Present at the RBC Capital Markets Healthcare Conference
4. Perrigo Announces the Launch of Loratadine-D 12 Store Brand Labels -- the First Store Brand Launch That Compares to Claritin-D® 12
5. Perrigo Company to Present at the Leerink Swann 2012 Global Healthcare Conference
6. Perrigo Company Announces Quarterly Dividend
7. Perrigo Confirms Filing for Generic Version of Astepro® Nasal Spray and Announcement of Patent Infringement Lawsuit by Meda Pharmaceuticals
8. Perrigo Wins Summary Judgment in Generic Mucinex® Case
9. Perrigo Acquires Assets of CanAm Care for $36 Million
10. Perrigo Company to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Zacks Industry Outlook Highlights: Vertex Pharma, Human Genome Sciences, Biogen Idec and Perrigo